| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.5 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.035 | 0.5 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.048 | 0.5 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |